摩根基金 - 基因治療主題基金 - JPM基因治療主題(美元) - A股(累計)
85.73美元0.73(0.84%)
2025/06/12更新
績效 / 1月7.81%
3月3.23%
1年10.61%
晨星評等-
- 1.現金0.58%
- 2.股票27.68%
- 3.債券0.00%
- 4.其他71.74%
- 1.美國71.73%
- 2.歐洲不包含歐元區9.73%
- 3.日本6.50%
- 4.新興亞洲3.70%
- 5.歐元區3.44%
- 1.Novartis AG Registered Shares3.21%
- 2.Alnylam Pharmaceuticals Inc3.14%
- 3.PTC Therapeutics Inc3.13%
- 4.Astellas Pharma Inc2.97%
- 5.Krystal Biotech Inc2.96%
- 6.Amgen Inc2.96%
- 7.Gilead Sciences Inc2.94%
- 8.Biomarin Pharmaceutical Inc2.84%
- 9.Bristol-Myers Squibb Co2.72%
- 10.Lonza Group Ltd2.67%
- 1.現金0.58%
- 2.股票27.68%
- 3.債券0.00%
- 4.其他71.74%
- 1.美國71.73%
- 2.歐洲不包含歐元區9.73%
- 3.日本6.50%
- 4.新興亞洲3.70%
- 5.歐元區3.44%
- 1.Novartis AG Registered Shares3.21%
- 2.Alnylam Pharmaceuticals Inc3.14%
- 3.PTC Therapeutics Inc3.13%
- 4.Astellas Pharma Inc2.97%
- 5.Krystal Biotech Inc2.96%
- 6.Amgen Inc2.96%
- 7.Gilead Sciences Inc2.94%
- 8.Biomarin Pharmaceutical Inc2.84%
- 9.Bristol-Myers Squibb Co2.72%
- 10.Lonza Group Ltd2.67%